1Hu S, Wang S, Fanelli, F, et al. Pancreatie β - cell KATP channel activity and membrane-binding studies with nateglinide: a comarison with sulfonylureas and repaglinide [ J ]. J Pharmacol Exp Ther 200,293(2) :444 - 452.
2Arahamian H Francescon: M, Loiskandl A, et al. Evaluation of a new insulinotropic a gent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring [J]. Diabetes Technol Ther 2004, 6(1) :31 - 37.
3Devineni D, Walter Y H, Smith H T, et al. Pharmcolcinetics of nateglinide in renally impaired diabertic patients[J]. J Clin Pharmacol 2003, 43(2) : 163 - 170.
4Weaver M C, Orwig B A, Rodriguez L C, et al. Pharmacokineties and metabocism of nateglinide in hamans[ J ]. Drug Metab Dispos 2001,29(4):415-421.
